JP2020517740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517740A5 JP2020517740A5 JP2020507722A JP2020507722A JP2020517740A5 JP 2020517740 A5 JP2020517740 A5 JP 2020517740A5 JP 2020507722 A JP2020507722 A JP 2020507722A JP 2020507722 A JP2020507722 A JP 2020507722A JP 2020517740 A5 JP2020517740 A5 JP 2020517740A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- pharmaceutical composition
- domain
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 229940123708 CD14 antagonist Drugs 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000002555 anti-neurodegenerative effect Effects 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 229940110394 C5a inhibitor Drugs 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 229940124073 Complement inhibitor Drugs 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 108010073240 complement C5a-inhibitors Proteins 0.000 claims 2
- 239000004074 complement inhibitor Substances 0.000 claims 2
- 201000010901 lateral sclerosis Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 201000002241 progressive bulbar palsy Diseases 0.000 claims 2
- 201000008752 progressive muscular atrophy Diseases 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 claims 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 claims 1
- VATFHFJULBPYLM-ILOBPARPSA-N PMX-205 Chemical group C([C@@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(NCCC[C@@H](C(=O)N2CCC[C@H]2C(=O)N1)NC(=O)CCC=1C=CC=CC=1)=O)CCCN=C(N)N)C1CCCCC1 VATFHFJULBPYLM-ILOBPARPSA-N 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical group C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 claims 1
- 229950009041 edaravone Drugs 0.000 claims 1
- 108010011646 hydrocinnamate-cyclo(ornithyl-prolyl-cyclohexylalanyl-tryptophyl-arginyl) Proteins 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 201000000196 pseudobulbar palsy Diseases 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023065903A JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901462 | 2017-04-21 | ||
| AU2017901462A AU2017901462A0 (en) | 2017-04-21 | Agents for treating or preventing motor neurone disease and uses therefor | |
| AU2018900762A AU2018900762A0 (en) | 2018-03-08 | “agents for treating disease and uses therefor” | |
| AU2018900762 | 2018-03-08 | ||
| PCT/AU2018/050357 WO2018191786A1 (en) | 2017-04-21 | 2018-04-20 | Cd 14 antagonist antibodies for treating neurodegenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023065903A Division JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517740A JP2020517740A (ja) | 2020-06-18 |
| JP2020517740A5 true JP2020517740A5 (OSRAM) | 2021-05-27 |
Family
ID=63855469
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507722A Pending JP2020517740A (ja) | 2017-04-21 | 2018-04-20 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
| JP2023065903A Pending JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023065903A Pending JP2023090751A (ja) | 2017-04-21 | 2023-04-13 | 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200148780A1 (OSRAM) |
| EP (1) | EP3612566A4 (OSRAM) |
| JP (2) | JP2020517740A (OSRAM) |
| KR (1) | KR20200015477A (OSRAM) |
| CN (1) | CN110831975A (OSRAM) |
| AU (1) | AU2018255489B2 (OSRAM) |
| IL (2) | IL309046B2 (OSRAM) |
| WO (1) | WO2018191786A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7371019B2 (ja) * | 2018-05-10 | 2023-10-30 | ザ・メソジスト・ホスピタル | 疾病の予後と管理のための方法 |
| PE20210186A1 (es) | 2018-07-13 | 2021-02-02 | Alector Llc | Anticuerpos anti-sortilina y metodos para su uso |
| CA3140023A1 (en) * | 2019-06-11 | 2020-12-17 | Alector Llc | Anti-sortilin antibodies for use in therapy |
| JP2022541646A (ja) * | 2019-07-25 | 2022-09-26 | インプリシット・バイオサイエンス・リミテッド | 急性神経炎症傷害を処置するための方法および薬剤 |
| AU2021219072B2 (en) * | 2020-02-13 | 2024-10-03 | Prilenia Neurotherapeutics Ltd. | Combination therapy for treating amyotrophic lateral using pridopidine and another active agent |
| CN113939533B (zh) * | 2020-06-18 | 2022-12-06 | 武汉全景生物技术有限公司 | 抗可溶性cd14亚型抗体、试剂盒及其应用 |
| EP4225796A4 (en) * | 2020-10-07 | 2024-11-13 | Line 6 Biotechnology, Inc | Methods and agents for the treatment of ocular disease |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117031014A (zh) * | 2023-08-14 | 2023-11-10 | 陕西脉元生物科技有限公司 | 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN118290585B (zh) * | 2024-06-04 | 2024-08-30 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd14工程抗体及应用 |
| CN120399098B (zh) * | 2025-07-03 | 2025-09-16 | 上海玄言生物科技有限公司 | 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69032662T2 (de) * | 1989-08-01 | 1999-03-11 | Rockefeller University, New York, N.Y. | Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis |
| CA2163976C (en) * | 1993-05-28 | 2010-06-29 | Didier J. Leturcq | Methods and compositions for inhibiting cd14 mediated cell activation |
| WO1996008272A1 (en) * | 1994-09-16 | 1996-03-21 | The Scripps Research Institute | Use of antibodies to block the effects of gram-positive bacteria and mycobacteria |
| JPWO2002042333A1 (ja) | 2000-11-22 | 2004-03-25 | 持田製薬株式会社 | Ｃｄ１４／ｔｌｒ結合阻害作用を有する抗ｃｄ１４モノクローナル抗体 |
| WO2006063292A1 (en) * | 2004-12-08 | 2006-06-15 | Icos Corporation | Recombinant method for making multimeric proteins |
| US20090181008A1 (en) * | 2005-11-10 | 2009-07-16 | Satoris, Inc. | Methods of treating alzheimer's disease |
| KR101256837B1 (ko) * | 2009-03-09 | 2013-04-22 | 경북대학교 산학협력단 | 가용성 ｃｄ１４의 파킨슨 병 진단 및 치료용 용도 |
| CN102869680B (zh) * | 2010-02-26 | 2016-10-05 | 生命北极神经科学公司 | 原细纤维结合抗体及其在帕金森氏症、路易体痴呆和其他α-共核蛋白病的治疗和诊断方法中的应用 |
| WO2018165720A1 (en) * | 2017-03-17 | 2018-09-20 | Implicit Bioscience Pty Ltd | Agents for treating or preventing viral infections and uses therefor |
| JP7371019B2 (ja) * | 2018-05-10 | 2023-10-30 | ザ・メソジスト・ホスピタル | 疾病の予後と管理のための方法 |
-
2018
- 2018-04-20 AU AU2018255489A patent/AU2018255489B2/en active Active
- 2018-04-20 JP JP2020507722A patent/JP2020517740A/ja active Pending
- 2018-04-20 EP EP18788123.0A patent/EP3612566A4/en active Pending
- 2018-04-20 IL IL309046A patent/IL309046B2/en unknown
- 2018-04-20 US US16/606,727 patent/US20200148780A1/en not_active Abandoned
- 2018-04-20 IL IL270097A patent/IL270097B2/en unknown
- 2018-04-20 CN CN201880040765.4A patent/CN110831975A/zh active Pending
- 2018-04-20 KR KR1020197033198A patent/KR20200015477A/ko not_active Ceased
- 2018-04-20 WO PCT/AU2018/050357 patent/WO2018191786A1/en not_active Ceased
-
2021
- 2021-09-23 US US17/483,517 patent/US12297287B2/en active Active
-
2023
- 2023-04-13 JP JP2023065903A patent/JP2023090751A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517740A5 (OSRAM) | ||
| JP2016513682A5 (OSRAM) | ||
| HRP20200241T1 (hr) | Anti-c5a vezujuće skupine s visokom blokirajućom aktivnosti | |
| JP2019522961A5 (OSRAM) | ||
| KR101649168B1 (ko) | 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도 | |
| JP2020513791A5 (OSRAM) | ||
| JP2020517249A5 (OSRAM) | ||
| JP2013500941A5 (OSRAM) | ||
| JP2017113028A5 (OSRAM) | ||
| JP2018512138A5 (OSRAM) | ||
| JP2020536888A5 (OSRAM) | ||
| JP2019054802A5 (OSRAM) | ||
| JP2016508496A5 (OSRAM) | ||
| JP2019527194A5 (OSRAM) | ||
| JP2009519718A5 (OSRAM) | ||
| JP2019505527A5 (OSRAM) | ||
| JP2011514150A5 (OSRAM) | ||
| JP2020502996A5 (OSRAM) | ||
| JP2009540018A5 (OSRAM) | ||
| JP2012504634A5 (OSRAM) | ||
| NZ585559A (en) | Humanized antibodies against tl1a | |
| JP2016527225A5 (OSRAM) | ||
| JP2015533795A5 (OSRAM) | ||
| JP2016136963A5 (OSRAM) | ||
| JP2019511911A5 (OSRAM) |